secwatch.observer — SEC 8-K summary
======================================

Issuer:     Surrozen, Inc./DE (SRZN)
CIK:        0001824893
Form:       8-K
Filed at:   2023-05-10T23:59:59+00:00
Accession:  0000950170-23-020519
Event type: earnings
Sentiment:  negative
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Surrozen Q1 net loss widens to $14.3M; cash at $61.7M; SZN-043 and SZN-1326 trials enroll
--------------------------------------------------------------------------------

- Net loss of $14.3M vs $7.9M in Q1 2022, driven by $1.2M restructuring charges and higher G&A.
- Cash, equivalents and marketable securities $61.7M, down from $75.8M at Dec 31, 2022.
- R&D expenses $8.1M, down from $9.4M YoY due to January 2023 restructuring reducing workforce ~25%.
- SZN-043 Phase 1a enrollment ongoing in chronic liver disease; safety data expected end of 2023.
- SZN-1326 Phase 1a re-initiated in Q2 2023; safety data also expected by end of 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1824893/000095017023020519/0000950170-23-020519-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1824893/000095017023020519/srzn-20230510.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-020519

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer